US FDA's Decade In Review: From Biosimilars To Real-World Evidence

 
• By Brenda Sandburg

A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.

Evolutionary Decade at FDA
FDA actions on biosimilars, opioids and real-world evidence shaped the past decade

More from US FDA

More from Agency Leadership